Table 1. Correlation between NUSAP1 expression and parameters in OSCCs.

			Results of immunostaining
			No. patients
Clinical classification		Total	NUSAP1(-)		NUSAP1(+)		p value
Age at surgery (years)
	<60	19	7	(35%)	12	(65%)	0.214
	60–70	27	5	(17%)	22	(83%)
	70>	24	4	(20%)	20	(80%)
Gender
	Male	40	9	(25%)	31	(75%)	0.512
	Female	30	7	(20%)	23	(80%)
T-primary tumor size
	T1	5	1	(20%)	4	(80%)	0.204
	T2	37	12	(32%)	25	(68%)
	T3	13	2	(10%)	11	(90%)
	T4	15	1	(6%)	14	(94%)
	T1+T2	42	13	(33%)	29	(67%)	0.048*
	T3+T4	28	3	(8%)	25	(92%)
N-regional lymph node
	Negative	39	11	(25%)	28	(75%)	0.533
	Positive	31	5	(21%)	26	(79%)
TNM stage
	I	5	1	(20%)	4	(80%)	0.691
	II	25	6	(24%)	19	(76%)
	III	21	4	(25%)	17	(75%)
	IV	19	5	(21%)	14	(79%)
Histopathological type
	Well-differentiated	43	9	(21%)	34	(79%)	0.456
	Moderately differentiated	16	5	(36%)	11	(64%)
	Poorly differentiated	11	2	(22%)	9	(78%)
Tumoral site
	Gingiva	15	3	(20%)	12	(80%)	0.552
	Tongue	40	10	(25%)	30	(75%)
	Buccal mucosa	6	1	(17%)	5	(83%)
	Oral floor	9	2	(22%)	7	(78%)
Total		70	16		54

NUSAP1(-), down-regulated NUSAP1; NUSAP1(+), up-regulated NUSAP1.

*p < 0.05. (χ2 test).